Incidence and factors associated with cutaneous immune-related adverse events to immune check point inhibitors: An ambispective cohort study DOI Creative Commons

Athitaya Luangnara,

Salin Kiratikanon, Thanika Ketpueak

et al.

Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13

Published: Oct. 20, 2022

Although immune checkpoint inhibitors (ICIs) have become the frontline treatment option for patients with various advanced cancers due to improved survival, they can be associated a spectrum of cutaneous immune-related adverse events (cirAEs). However, little is known regarding occurrence and patterns cirAE-related ICI therapy in different races other than white populations. Therefore, we investigated incidence factors cirAEs among cancer northern Thailand.A referral-center-based ambispective cohort study was conducted from January 1, 2017, March 31, 2021. Based on linked database merged patient-level data, adult pathologically confirmed who were diagnosed received regardless type followed up through August 2021, included. All based clinical evaluation ascertainment by board-certified dermatologist. The confidence intervals (CIs) across cancer- therapy-specific groups estimated. Factors evaluated using multivariable modified Poisson regression estimate risk ratios (RRs) 95% CIs.The included 112 (67 men [59.8%]; mean age, 65.0 [range, 31.0-88.0] years), mainly lung (56.3%), liver (19.6%). overall 32.1% (95% CI, 24.1-41.4); however, there no substantial difference sex, type, or individual therapy. two identified prognostic age >75 years (adjusted RR, 2.13; 1.09-4.15; P=0.027) pre-existing chronic kidney disease stages 3-4 3.52; 2.33-5.31; P<0.001).The Thai comparable that Early identification, particularly elderly those CKD, should implemented practice help optimize therapeutic decision-making patient health outcomes.

Language: Английский

Increased presentation for vitiligo cutaneous immune related adverse events in Hispanic patients DOI
Zoha Momin, Jennifer G. Gill, Meghan Heberton

et al.

Archives of Dermatological Research, Journal Year: 2024, Volume and Issue: 316(6)

Published: May 31, 2024

Language: Английский

Citations

0
Immune Checkpoint Inhibitor-Associated Cutaneous Adverse Events: Mechanisms of Occurrence DOI Open Access

Abdulaziz M. Eshaq,

Thomas W. Flanagan,

Anass Abbad

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 26(1), P. 88 - 88

Published: Dec. 26, 2024

Immunotherapy, particularly that based on blocking checkpoint proteins in many tumors, including melanoma, Merkel cell carcinoma, non-small lung cancer (NSCLC), triple-negative breast (TNB cancer), renal cancer, and gastrointestinal endometrial neoplasms, is a therapeutic alternative to chemotherapy. Immune inhibitor (ICI)-based therapies have the potential target different pathways leading destruction of cells. Although ICIs are an effective treatment strategy for patients with highly immune-infiltrated cancers, development adverse effects cutaneous during after common. ICI-associated include mostly inflammatory bullous dermatoses, as well severe side reactions such rash or dermatitis encompassing erythema multiforme; lichenoid, eczematous, psoriasiform, morbilliform lesions; palmoplantar erythrodysesthesia. The immunotherapy-related consequence ICIs’ unique molecular action mainly mediated by activation cytotoxic CD4+/CD8+ T disorders most prevalent induced response anti-programmed death 1 (PD-1), anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), ligand (PD-L1) agents. Herein, we will elucidate mechanisms regulating occurrence following ICIs.

Language: Английский

Citations

0
Mechanisms underlying immune-related adverse events during checkpoint immunotherapy DOI
Xiao Zhou, Xiang Chen, Leng Han

et al.

Clinical Science, Journal Year: 2022, Volume and Issue: 136(10), P. 771 - 785

Published: May 1, 2022

Abstract Immune checkpoint (IC) proteins are some of the most important factors that tumor cells hijack to escape immune surveillance, and inhibiting ICs enhance or relieve antitumor immunity has been proven efficient in treatment. blockade (ICB) agents such as antibodies blocking programmed death (PD) 1, PD-1 ligand (PD-L) cytotoxic T lymphocyte-associated antigen (CTLA)-4 have approved by U.S. Food Drug Administration (FDA) treat several types cancers. Although ICB shown outstanding clinical success, their application continued expand additional past decade, immune-related adverse events (irAEs) observed a wide range patients who receive Numerous studies focused on manifestations pathology ICB-related irAEs, but detailed mechanisms underlying irAEs remain largely unknown. Owing expression IC molecules distinct cell subpopulations fact generally affect IC-expressing cells, influences need be determined. Here, we discuss functions potential mechanism(s) related ICB-targeted subsets irAEs.

Language: Английский

Citations

2
Incidence and factors associated with cutaneous immune-related adverse events to immune check point inhibitors: An ambispective cohort study DOI Creative Commons

Athitaya Luangnara,

Salin Kiratikanon, Thanika Ketpueak

et al.

Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13

Published: Oct. 20, 2022

Although immune checkpoint inhibitors (ICIs) have become the frontline treatment option for patients with various advanced cancers due to improved survival, they can be associated a spectrum of cutaneous immune-related adverse events (cirAEs). However, little is known regarding occurrence and patterns cirAE-related ICI therapy in different races other than white populations. Therefore, we investigated incidence factors cirAEs among cancer northern Thailand.A referral-center-based ambispective cohort study was conducted from January 1, 2017, March 31, 2021. Based on linked database merged patient-level data, adult pathologically confirmed who were diagnosed received regardless type followed up through August 2021, included. All based clinical evaluation ascertainment by board-certified dermatologist. The confidence intervals (CIs) across cancer- therapy-specific groups estimated. Factors evaluated using multivariable modified Poisson regression estimate risk ratios (RRs) 95% CIs.The included 112 (67 men [59.8%]; mean age, 65.0 [range, 31.0-88.0] years), mainly lung (56.3%), liver (19.6%). overall 32.1% (95% CI, 24.1-41.4); however, there no substantial difference sex, type, or individual therapy. two identified prognostic age >75 years (adjusted RR, 2.13; 1.09-4.15; P=0.027) pre-existing chronic kidney disease stages 3-4 3.52; 2.33-5.31; P<0.001).The Thai comparable that Early identification, particularly elderly those CKD, should implemented practice help optimize therapeutic decision-making patient health outcomes.

Language: Английский

Citations

1